The role of aromasin in the hormonal therapy of breast cancer

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Pathology Oncology Research

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF03033716PMID 12172571
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison of biochemical aromatase activity with aromatase immunhistochemistry in human breast carcinomas

  2004cited by this paper
• Aromatase inhibitors — mechanisms of steroidal inhibitors

  2004cited by this paper
• Advances in aromatase inhibition: clinical efficacy and tolerability in the treatment of breast cancer.

  2001cited by this paper
• Exemestane in advanced breast cancer

  2000cited by this paper
• Exemestane (Aromasin) is active and well tolerated as first-line hormonal therapy (HT) of metastatic breast cancer (MBC) patients (pts): results of a randomized phase II trial

  2000cited by this paper
• Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

  2000cited by this paper
• High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment.

  2000cited by this paper
• Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial.

  2000cited by this paper
• Biology of aromatase inhibitors: pharmacology/endocrinology within the breast.

  1999cited by this paper
• Effects of aromatase inhibitors on the pathobiology of the human breast, endometrial and ovarian carcinoma.

  1999cited by this paper
• Hormonal therapy in breast cancer and predominant visceral disease: effectiveness of the new oral aromatase inactivator, Aromasin® (exemestane), in advanced breast cancer patients having progressed on antiestrogens

  1999cited by this paper
• Multicenter, Phase II Trial of Exemestane as Third-Line Hormonal Therapy of Postmenopausal Women With Metastatic Breast Cancer

  1999cited by this paper
• Multicenter, phase II trial of exemestane as third-line hormonal therapy of postmenopausal women with metastatic breast cancer. Aromasin Study Group.

  1999cited by this paper
• Aromatase inhibitors and enzyme stability.

  1999cited by this paper
• Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients.

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study.

  1997cited by this paper
• Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group.

  1997cited by this paper
• Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients.

  1996cited by this paper
• Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer.

  1996cited by this paper
• Novel aromatase and 5α-reductase inhibitors

  1994cited by this paper
• Novel aromatase and 5 alpha-reductase inhibitors.

  1994cited by this paper
• Exemestane (FCE 24304), a new steroidal aromatase inhibitor.

  1992cited by this paper
• 6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor.

  1988cited by this paper
• 4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer.

  1984cited by this paper
• Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo.

  1981cited by this paper
• Treatment of metastatic disease.

  1979cited by this paper
• A possible new approach to the treatment of metastatic breast cancer: massive doses of medroxyprogesterone acetate.

  1978cited by this paper
• Letter: Woodpecker's tongues.

  1976cited by this paper
• A New Anti-oestrogenic Agent in Late Breast Cancer: An Early Clinical Appraisal of ICI46474

  1971cited by this paper
• Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial.

  1967cited by this paper
• Cortisone treatment of metastatic breast cancer.

  1959cited by this paper
• [Hypophysectomy in man].

  1953cited by this paper
• Adrenalectomy and oophorectomy in treatment of advanced carcinoma of the breast.

  1953cited by this paper
• Hypophysectomy in Man*

  1952cited by this paper
• On the Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for a New Method of Treatment, with Illustrative Cases

  1896cited by this paper

• Recent Prospectives of Cellular Signaling Role for Mammary Gland Carcinogenesis.

  2025cites this paper
• A comprehensive review on nanocarriers as a targeted delivery system for the treatment of breast cancer

  2024cites this paper
• Rapid Induction of Female-to-Male Sex Change in Adult Zebrafish by Injection of an Aromatase Inhibitor

  2020cites this paper
• Clinical and molecular aspects of breast cancer: Targets and therapies.

  2018cites this paper
• FACULTAD DE FARMACIA UNIVERSIDAD COMPLUTENSE

  2015cites this paper
• AROMATASE INHIBITORS : A NEW HOPE FOR BREAST CANCER PATIENTS

  2010cites this paper
• Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone

  2009cites this paper
• Exemestane in early breast cancer: a review

  2008cites this paper
• Exemestane: A milestone against breast cancer Exemestane: A milestone against breast cancer Exemestane: A milestone against breast cancer Exemestane: A milestone against breast cancer Exemestane: A milestone against breast cancer

  2007cites this paper
• Exemestane: a milestone against breast cancer.

  2007cites this paper
• Prevention of breast cancer: current state of the science and future opportunities

  2006cites this paper
• Sex control strategies in aquaculture: A systematic review of aromatase inhibition

  year unknowncites this paper